Navigation Links
PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
Date:5/15/2013

Cary, NC (PRWEB) May 15, 2013

PharmaDirections has added another issued patent to their list of patents where they helped invent new technology for their clients. This one is United States Patent 8,318,788 which has been issued for “Layered Pharmaceutical Formulations”. This was a second patent that was a result of a collaborative formulation development effort between the scientists at Orexigen, PharmaDirections and their sub-contractors.

The technology is for multiple layered pharmaceutical formulations for drug products such as Contrave®, a treatment for obesity. The patent is assigned to Orexigen Therapeutics, Inc. who currently has an NDA for Contrave® under review at the FDA. In the example of an oral, controlled release dosage formulation, the middle layer is inert and dissolves in vivo to leave two separated drug containing layers intact until dissolution begins. This was done to separate potentially interacting layers from one another within the tablet and to allow each pharmaceutical layer to have its own controlled release dissolution profile. The pharmacokinetic modeling and formulation design was done at PharmaDirections.

"Our collaborative effort with Orexigen resulted in multiple accomplishments including this issued patent and the submission of 4 other patent submissions,” said Dr. Richard Soltero, President of PharmaDirections. “This brings us to 21 issued and issued patents for our clients where a PharmaDirections staff member was one of the inventors. We have helped a lot pharmaceutical companies find additional intellectual property by solving problems of bioavailability, stability or off-label competition.”

During the period from 2005 to 2008, PharmaDirections developed and manufactured several products for Orexigen including Contrave® and Empatic™. This relationship was published in Orexigen’s S-1statement issued in 2005 where it noted: “PharmaDirections is our primary drug development consultant and manages subcontractors on our behalf.”

About PharmaDirections:

PharmaDirections is a pharmaceutical project management and consulting group focused on CMC (Chemistry, Manufacturing and Controls), formulation development, preclinical and regulatory affairs. They utilize a mix of technical expertise, software and proprietary tools, such as GastroPlus™, when inventing new intellectual property for clients or developing formulations that solve difficult problems.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10720248.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
2. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
3. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
4. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
5. The Second Rarest Job in America: Atlanta Dentist Discusses New Bureau of Labor Statistics that Reveal Low Number of Prosthodontists
6. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
7. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
8. Rust Remover That Clears Rust in Seconds Revealed by My Cleaning Products, Company Gives Out Samples of Product to Affirm Effectiveness
9. Genuine Bio Fuel Inc.’s Second Chance Program Proves to Be a Model for Successful Hiring in the Biodiesel Industry
10. Amgen Announces 2013 Second Quarter Dividend
11. Organic-Based Bed Bug Spray Kills Bed Bugs in Seconds, My Cleaning Products Releases Samples of the Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ... 21 st .  The commercials will air on Bloomberg TV, ... the Street show. --> NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ...
Breaking Biology News(10 mins):